Loading stock data…
ENOV
$24.78-1.74 (-6.56%)
After Hours$24.47-0.31 (-1.25%)· Last close May 11
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enovis Corporation in the Healthcare sector is trading at $24.78. The stock is currently 35% below its 52-week high of $37.85, remaining 8.6% below its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why ENOV maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.78
Potential Upside
5%
Whystock Fair Value$26.02
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$43.00+73.5%
Range$33.00 – $55.00
Fundamentals
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Preventi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.37B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.55%
Volume
Today's trading volume
1.31M
Recent News
Enovis Q1 Earnings Call Highlights
Enovis (NYSE:ENOV) reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula. On the company’s first-quarter earnings call, Chief Execu
Enovis (ENOV) Q1 2026 Earnings Transcript
In the first quarter, we delivered organic revenue growth of 3% with 6% organic growth in Recon and 1% organic growth in Prevention & Recovery. On a days adjusted basis, organic growth was 6% at the company level with 8% growth in Recon and 3% growth in P&R. In U.S. Recon, we grew 8% organically in the first quarter, led by 10% organic growth in extremities.
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
Enovis (ENOV) delivered earnings and revenue surprises of +8.54% and +3.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Enovis (NYSE:ENOV) Exceeds Q1 CY2026 Expectations
Medical technology company Enovis Corporation (NYSE:ENOV) announced better-than-expected revenue in Q1 CY2026, with sales up 5.4% year on year to $589.2 million. The company expects the full year’s revenue to be around $2.34 billion, close to analysts’ estimates. Its non-GAAP profit of $0.89 per share was 9.9% above analysts’ consensus estimates.
KORU Medical Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems, Inc. (KRMD) delivered earnings and revenue surprises of -33.33% and +3.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?